Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001826 · ClinicalTrials.gov registry record
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
A clinical trial of HIV Infection, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT00001826 is a study of HIV Infection that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001826, a study of HIV Infection, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will continue to follow children who participated in an earlier National Cancer Institute trial of HIV treatment with a protease inhibitor. Children in this study will receive a combination of at least three drugs that include at least one protease inhibitor and one reverse transcriptase inhibitor. The study will examine to what extent these drugs can restore immune function in HIV-infected children and over what length of time. It will look at changes in the amounts of virus and the specific types of immune cells in the body over the 96-week trial period. It will also examine patients' immune system response to influenza and tetanus vaccinations. The children will either continue to receive the anti-HIV drugs they have been taking, or their medicines will be changed to a different combination of protease inhibitor and reverse transcriptase inhibitor. Before and during the study, patients will undergo various tests, including a physical examination, blood tests and chest X ray, immune response tests, CT scan, eye examination, electrocardiogram and echocardiogram. A procedure called apheresis may be done to collect white blood cells. In this procedure, whole blood is drawn similar to donating blood, the white cells are separated out by a machine, and the red cells are returned to the body.
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1999-07 |
| Est. Completion | 2006-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001826
The ClinicalTrials.gov registry entry for NCT00001826 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (79% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 0 interventions.
NCT00001826 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001826 about?
NCT00001826 is a clinical study titled "Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor". This study will continue to follow children who participated in an earlier National Cancer Institute trial of HIV treatment with a protease inhibitor. Children in this study will receive a combination of at least three drugs that include at least one protease inhibitor and one reverse transcriptase ...
What is the current status of trial NCT00001826?
This trial is currently completed. The enrollment target is 50 participants. The study started on 1999-07. Estimated completion is 2006-05.
What conditions does trial NCT00001826 study?
This clinical trial studies the following conditions: HIV Infection.
Who is sponsoring clinical trial NCT00001826?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001826 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
MAPS PrEP Van Study
RECRUITING · Phase 4
-
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
RECRUITING · NA
-
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
RECRUITING · NA
-
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.